Cargando…

Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis

BACKGROUND: The early identification of patients at risk of dying from community-acquired pneumonia (CAP) is critical for their treatment and for defining hospital resource consumption. Mid-regional pro-adrenomedullin (MR-proADM) has been extensively investigated for its prognostic value in CAP. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Dan, Xie, Lixin, Zhao, Haiyan, Liu, Xueyao, Cao, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881068/ https://www.ncbi.nlm.nih.gov/pubmed/27230573 http://dx.doi.org/10.1186/s12879-016-1566-3

Ejemplares similares

Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review
por: Önal, Uğur, et al.
Publicado: (2018)

Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study
por: Montrucchio, Giorgia, et al.
Publicado: (2021)

Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study
por: Vigué, Bernard, et al.
Publicado: (2016)

MR-proADM as prognostic factor of outcome in COVID-19 patients
por: Sozio, Emanuela, et al.
Publicado: (2021)

MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients
por: Cameli, Paolo, et al.
Publicado: (2023)

Dataset of the associations of aldosterone to renin ratio with MR-proANP and MR-proADM
por: Then, Cornelia, et al.
Publicado: (2016)

MR-proADM and MR-proANP levels in patients with acute pulmonary embolism
por: Öner, Önsel, et al.
Publicado: (2020)

Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score
por: Travaglino, Francesco, et al.
Publicado: (2012)

The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections
por: Baumann, Philipp, et al.
Publicado: (2022)

Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study
por: Graziadio, Sara, et al.
Publicado: (2018)

Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients
por: Fialek, Bartosz, et al.
Publicado: (2023)

Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients
por: García de Guadiana-Romualdo, Luis, et al.
Publicado: (2021)

Application of MR-ProADM to predict prevention of hospitalisation, derived from a multi-centre study
por: Cullinan, Milo, et al.
Publicado: (2019)

Role of MR-proADM in the risk stratification of COVID-19 patients assessed at the triage of the Emergency Department
por: Minieri, Marilena, et al.
Publicado: (2021)

Predictive Value of MR-proADM in the Risk Stratification and in the Adequate Care Setting of COVID-19 Patients Assessed at the Triage of the Emergency Department
por: Minieri, Marilena, et al.
Publicado: (2022)

Mid-Regional Proadrenomedullin (MR-proADM) and Microcirculation in Monitoring Organ Dysfunction of Critical Care Patients With Infection: A Prospective Observational Pilot Study
por: Domizi, Roberta, et al.
Publicado: (2021)

1542. MR-proADM Biomarker Predicts COVID-19 Clinical Outcomes: a US-based Cohort Study
por: Mansour, Michael
Publicado: (2022)

Short‐Term Influence of Radiofrequency Ablation on NT‐proBNP, MR‐proANP, Copeptin, and MR‐proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study
por: Charitakis, Emmanouil, et al.
Publicado: (2016)

Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium
por: Sujana, Chaterina, et al.
Publicado: (2022)

Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control
por: Iwao, Motoshi, et al.
Publicado: (2021)

Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study
por: Gar, Christina, et al.
Publicado: (2022)

Response to: MR-proADM has a good ability to predict mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!
por: van Oers, Jos A.H., et al.
Publicado: (2022)

MR‐proADM as a Prognostic Marker in Patients With ST‐Segment–Elevation Myocardial Infarction—DANAMI‐3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy
por: Falkentoft, Alexander C., et al.
Publicado: (2018)

MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!
por: Honore, Patrick M., et al.
Publicado: (2022)

Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB
por: Legramante, Jacopo Maria, et al.
Publicado: (2017)

Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study
por: Christ-Crain, Mirjam, et al.
Publicado: (2005)

Pro-adrenomedullin as prognostic biomarker in the sepsis
por: De La Torre-Prados, M, et al.
Publicado: (2013)

Prognostic value of pro-adrenomedullin and copeptin in acute infective endocarditis
por: Zampino, Rosa, et al.
Publicado: (2021)

Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]
por: Christ-Crain, Mirjam, et al.
Publicado: (2006)

Prognostic value of pro-atrial natriuretic peptide, pro-adrenomedullin, and pro-endothelin-1 in critically ill patients
por: Bloos, F, et al.
Publicado: (2006)

Diagnostic and prognostic usefulness of mid-regional pro-adrenomedullin levels in patients with severe sepsis
por: Valenzuela Sanchez, F, et al.
Publicado: (2015)

Mid-Regional Pro-Adrenomedullin as a Prognostic Factor for Severe COVID-19 ARDS
por: de Montmollin, Etienne, et al.
Publicado: (2022)

The Association of Mid-Regional Pro-Adrenomedullin and Mid-Regional Pro-Atrial Natriuretic Peptide with Mortality in an Incident Dialysis Cohort
por: Gouya, Ghazaleh, et al.
Publicado: (2011)

Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness
por: Lippi, Giuseppe, et al.
Publicado: (2021)

The TRIAGE-ProADM Score for an Early Risk Stratification of Medical Patients in the Emergency Department - Development Based on a Multi-National, Prospective, Observational Study
por: Kutz, Alexander, et al.
Publicado: (2016)

Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study
por: Sardà Sánchez, Marta, et al.
Publicado: (2012)

Plasma mid‐regional pro‐adrenomedullin: A biomarker of the ischemic penumbra in hyperacute stroke
por: Ishiyama, Hiroyuki, et al.
Publicado: (2022)

Diagnostic value of mid-regional pro-Adrenomedullin as a biomarker of invasive bacterial infection in children: a systematic review
por: Corr, Michael Paul, et al.
Publicado: (2022)

Mid-regional pro-adrenomedullin and lactate levels for risk stratification in patients with out-of-hospital cardiac arrest
por: Zelniker, Thomas A, et al.
Publicado: (2023)

Mid regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study
por: Viaggi, Bruno, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fvkg052ap9k5ggec0q2dv7mbvb